Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (151-160 of 627) with videos related to

Pageof 63
Sort By:
The American Journal of Cardiology|January 28, 2010
Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI)John K French, Anne S Hellkamp, Paul W Armstrong, et al.
Journal of the American Society of Nephrology : JASN|July 23, 2020
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS ProgramMegumi Oshima, Bruce Neal, Tadashi Toyama, et al.
American Heart Journal|July 31, 2013
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conductRenato D Lopes, Sheila Dickerson, Gail Hafley, et al.
Diabetes, Obesity & Metabolism|January 26, 2017
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trialBruce Neal, Vlado Perkovic, David R Matthews, et al.
Journal of the American Society of Nephrology : JASN|September 19, 2019
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS ProgramBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
European Heart Journal|May 6, 2005
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trialPierre Théroux, Paul W Armstrong, Kenneth W Mahaffey, et al.
Trials|June 21, 2013
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapyRenato D Lopes, Yuliya Lokhnygina, Victor Hasselblad, et al.
American Heart Journal|December 21, 2018
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trialClaes Held, Harvey D White, Ralph A H Stewart, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 22, 2022
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE TrialDavid M Charytan, Jie Yu, Meg J Jardine, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 12, 2025
Deep Learning Chest X-Ray Age, Epigenetic Aging Clocks and Associations with Age-Related Subclinical Disease in the Project Baseline Health StudyJay Chandra, Sarah Short, Fatima Rodriguez, et al.
Pageof 63

Showing results (151-160 of 627) with videos related to

Sort By:
Pageof 63
The American Journal of Cardiology|January 28, 2010
Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI)John K French, Anne S Hellkamp, Paul W Armstrong, et al.
Journal of the American Society of Nephrology : JASN|July 23, 2020
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS ProgramMegumi Oshima, Bruce Neal, Tadashi Toyama, et al.
American Heart Journal|July 31, 2013
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conductRenato D Lopes, Sheila Dickerson, Gail Hafley, et al.
Diabetes, Obesity & Metabolism|January 26, 2017
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trialBruce Neal, Vlado Perkovic, David R Matthews, et al.
Journal of the American Society of Nephrology : JASN|September 19, 2019
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS ProgramBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
European Heart Journal|May 6, 2005
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trialPierre Théroux, Paul W Armstrong, Kenneth W Mahaffey, et al.
Trials|June 21, 2013
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapyRenato D Lopes, Yuliya Lokhnygina, Victor Hasselblad, et al.
American Heart Journal|December 21, 2018
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trialClaes Held, Harvey D White, Ralph A H Stewart, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 22, 2022
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE TrialDavid M Charytan, Jie Yu, Meg J Jardine, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 12, 2025
Deep Learning Chest X-Ray Age, Epigenetic Aging Clocks and Associations with Age-Related Subclinical Disease in the Project Baseline Health StudyJay Chandra, Sarah Short, Fatima Rodriguez, et al.
Pageof 63